Mucoepidermoid carcinoma of minor salivary glands.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Y C Mishra.
Explore the source record for details and available documents.
A rare case of primary oral malignant melanoma with widespread metastasis to nose, lacrimal passages, face and liver has been described.
Neuralgia due to pressure on the inferior alveolar nerve by an impacted third molar is not uncommon but the entrapment of the nerve within the substance of the tooth is rare. When such a case is encountered, the removal of the tooth is indicated to relieve pain. The removal of the tooth usually results in a degree of impairment of sensation in the area supplied by the nerve, for a period of time. However, if care is taken to preserve the nerve during surgery, the period of impaired sensation can be shortened. An impacted tooth involving the inferior alveolar nerve but not producing symptoms should not be removed.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Unilateral ocular myasthenia gravis is being reported. He had significant involvement of one eye with no involvement of the fellow eye.
Atenolol is a newer betablocker, widely used as an antihypertensive drug. It cause a large and rapid fall in IOP when used orally and topically. A total of 33 patients both having normal and raised IOP were included in the study. The drug was given in a dose of 50 mg. tab. orally once a day for 7 days at 8 A.M. and IOP recorded after 24 hours, 72 hours and on 7th day. It produces significant and sustained fall in IOP in both normal and raised IOP patients besides lowering of systematic B.P. and pulse rate. The IOP on patients with systemic hypertension with Atenolol will be reduced and stoppage of therapy may cause glaucoma damage.